Drugs / Iparomlimab and Tuvonralimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07129018 | Nov 2025 → Nov 2027 expected | biliary tract cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07129018 ↗ |
| Route | Intravenous | “Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w)” NCT07129018 ↗ |